Fortified S-Allyl L-Cysteine: Animal Safety, Effect on Retinal Ischemia, and Role of Wnt in the Underlying Therapeutic Mechanism

Table 3

The effect on electroretinogram b-wave amplitudes (mV) changes after oral gavage for 4 weeks of preischemia daily doses of SAC or Vehicle treatment.

Time/group	Vehicle	SAC 0.18 mg	SAC 0.018 mg	SAC 0.0018 mg
Baseline	0.43 ± 0.03	0.41 ± 0.05	0.48 ± 0.06	0.41 ± 0.07
Week 1	0.49 ± 0.05	0.44 ± 0.05	0.44 ± 0.06	0.45 ± 0.06
Week 2	0.43 ± 0.07	0.37 ± 0.06	0.46 ± 0.10	0.47 ± 0.08
Week 3	0.41 ± 0.07	0.35 ± 0.04	0.44 ± 0.06	0.40 ± 0.01
Week 4	0.35 ± 0.04	0.38 ± 0.05	0.44 ± 0.03	0.41 ± 0.04

The ERG amplitudes of a- and b-waves were recorded at the baseline (0 week) or 1/2/3/4 weeks after oral gavage of daily doses of vehicle or SAC (0.18, 0.018, or 0.0018 mg). The results are recorded without following ischemia and represented as mean ± S.E.M. (n = 6∼11). ERG, electroretinogram; SAC, S-allyl L-cysteine.